Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 13/20 | 0.46 |
| ▸ | HTR1B | P28222 | 13/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 12/20 | 0.42 |
| ▸ | HTR6 | P50406 | 7/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812001 | 0.83 | HTR1D (0.53) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6817232 | 0.81 | HTR1D (0.67) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6812630 | 0.80 | HTR1D (0.48) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6808890 | 0.77 | KDM4E (0.52) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6812249 | 0.77 | MCHR1 (0.61) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6808869 | 0.77 | HTR1D (0.50) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6817253 | 0.76 | HTR1A (0.53) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL7883944 | 0.75 | POLB (0.55) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL6812074 | 0.72 | HTR1A (0.45) | HTR1DHTR1BHTR2AHTR1AHTR6 | |
| SCHEMBL9301655 | 0.71 | HTR1D (0.55) | HTR1DHTR1BHTR2AHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132742-A1 | Novel compounds | BROMIDGE STEVEN MARK (GB) | 2004-07-08 | — | — | US | claimed |
| US-20030144505-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | claimed |
| US-20010051719-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2001-12-13 | — | — | US | claimed |
| EP-0946551-A2 | N-PIPERAZIN-1-YLPHENYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027058-A2 | N-PIPERAZIN-1-YLPHENYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| US-20040132742-A1 | Novel compounds | BROMIDGE STEVEN MARK (GB) | 2004-07-08 | — | — | US | disclosed |
| US-20030144505-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | disclosed |
| US-20010051719-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144505-A1 | Novel compounds | HTR1F, HTR6, HTR3C | HTR1D 5/4885HTR1B 9/4885HTR2A 35/4885 |
| US-20040132742-A1 | Novel compounds | CNR2, CNR1, ATP6V1B2 | HTR1D 146/4885HTR1B 91/4885HTR2A 77/4885 |
| US-20010051719-A1 | Novel compounds | CNR2, CNR1, ATP6V1B2 | HTR1D 284/4885HTR1B 157/4885HTR2A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.